1. Academic Validation
  2. Laser-responsive erastin-loaded chondroitin sulfate nanomedicine targeting CD44 and system xc- in liver cancer: A non-ferroptotic approach

Laser-responsive erastin-loaded chondroitin sulfate nanomedicine targeting CD44 and system xc- in liver cancer: A non-ferroptotic approach

  • J Control Release. 2024 Nov:375:574-588. doi: 10.1016/j.jconrel.2024.09.029.
So-Yeol Yoo 1 Hyun Young Kim 2 Dong Hyun Kim 3 Wan Seob Shim 2 Sang Min Lee 2 Dong Hwan Lee 3 Jang Mo Koo 3 Ji Hoon Yoo 3 Seokjin Koh 3 Jong Chan Park 3 Jieun Yu 3 Jang Su Jeon 3 Min-Jun Baek 2 Dae-Duk Kim 4 Ji-Yoon Lee 5 Soo Jin Oh 6 Sang Kyum Kim 7 Jae-Young Lee 8 Keon Wook Kang 9
Affiliations

Affiliations

  • 1 College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
  • 2 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
  • 3 College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea.
  • 4 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea; Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea.
  • 5 Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
  • 6 Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea; Department of Pharmacology, College of Medicine, University of Ulsan, Seoul, 05505, Republic of Korea.
  • 7 College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea. Electronic address: sangkim@cnu.ac.kr.
  • 8 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea; Natural Products Research Institute, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: lee.jy@snu.ac.kr.
  • 9 College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: kwkang@snu.ac.kr.
Abstract

Erastin, a ferroptosis-inducing system xc- inhibitor, faces clinical challenges due to suboptimal physicochemical and pharmacokinetic properties, as well as relatively low potency and off-target toxicity. Addressing these, we developed ECINs, a novel laser-responsive erastin-loaded nanomedicine utilizing indocyanine green (ICG)-grafted chondroitin sulfate A (CSA) derivatives. Our aim was to improve erastin's tumor targeting via CSA-CD44 interactions and enhance its antitumor efficacy through ICG's photothermal and photodynamic effects in the laser-on state while minimizing off-target effects in the laser-off state. ECINs, with their nanoscale size of 186.7 ± 1.1 nm and high erastin encapsulation efficiency of 93.0 ± 0.8%, showed excellent colloidal stability and sustained drug release up to 120 h. In vitro, ECINs demonstrated a mechanism of Cancer cell inhibition via G1-phase cell cycle arrest, indicating a non-ferroptotic action. In vivo biodistribution studies in SK-HEP-1 xenograft mice revealed that ECINs significantly enhanced tumor distribution of erastin (1.9-fold greater than free erastin) while substantially reducing off-target accumulation in the lungs and spleen by 203-fold and 19.1-fold, respectively. Combined with laser irradiation, ECINs significantly decreased tumor size (2.6-fold, compared to free erastin; 2.4-fold, compared to ECINs without laser irradiation) with minimal systemic toxicity. This study highlights ECINs as a dual-modality approach for liver Cancer treatment, demonstrating significant efficacy against tumors overexpressing CD44 and system xc-.

Keywords

CD44–xCT axis; Cell cycle arrest; Chondroitin sulfate a nanomedicine; Erastin; Hepatocellular carcinoma; Photothermal and photodynamic therapy.

Figures
Products